Cellectar Biosciences develops proprietary oncology drugs built around its Phospholipid Drug Conjugate™ (PDC) delivery platform. News about CLRB commonly centers on targeted radiotherapeutic programs, including iopofosine I 131 for Waldenström macroglobulinemia and CLR 121125, also called CLR 125, an iodine-125 Auger-emitting program for solid tumors such as triple negative breast, lung and colorectal cancers.
Company updates also cover clinical data from the CLOVER WaM study, oncology conference presentations, European and U.S. regulatory interactions, intellectual property protection, securities financings, and periodic financial results with corporate updates. The recurring disclosures reflect a late-stage clinical biopharmaceutical company funding and advancing cancer-cell-targeting treatments through internal development and research collaborations.
Cellectar Biosciences (NASDAQ: CLRB) reported strong results for Q1 2020 with CLR 131 achieving primary efficacy endpoints in clinical studies for relapsed/refractory cancers. Key highlights include:
- 42.8% overall response rate in r/r multiple myeloma (MM)
- 100% ORR in r/r Lymphoplasmacytic lymphoma/Waldenstrom’s macroglobulinemia
- Orphan Drug Designation from the FDA for CLR 131
- Cash and cash equivalents at $7.1 million
However, the company recorded a net loss of $4.0 million, indicating continued investment in R&D.